1.Lilly Research Laboratories,Eli Lilly & Co,Indianapolis,USA;2.The Lewin Group,Falls Church,USA;3.Dept of Surgery, Harvard Medical School,Brigham and Women's Hospital,Boston,USA
Abstract:
Background
To assess the measurement properties of the Benign Prostatic Hyperplasia Impact Index (BII) for use in men with Lower Urinary Tract Symptoms (LUTS) secondary to Benign Prostatic Hyperplasia (BPH) treated with tadalafil.